Ecolab (ECL) Q3 2024 earnings summary

Executive summary

• Achieved strong Q3 2024 growth with reported sales of $4.0 billion, up 1% year-over-year, and organic sales up 4%, despite a 2% headwind from the sale of the global surgical solutions business and 1% from currency exchange.

• Adjusted diluted EPS rose 19% to $1.83; reported diluted EPS was $2.58, up 83% year-over-year, driven by a major gain from the surgical solutions business sale.

• Reported operating income increased 85% to $1.04 billion; organic operating income up 22%.

• Volume growth accelerated to 2% on new business wins and innovation; value pricing remained in the 2–3% target range.

• Raised full-year 2024 adjusted diluted EPS outlook to $6.60–$6.70, a 27–29% increase over 2023, with strong momentum into 2025.

Financial highlights

• Q3 2024 net sales: $3.99–$4.0 billion (+1%); organic sales up 4%; nine months: $11.74 billion (+3%).

• Gross margin expanded 220–230 bps to 43.4%–43.5% year-over-year.

• Organic operating income margin expanded 260 bps to 17.9%; reported operating income margin reached 26.1%.

• Cash from operations for the nine months ended September 30, 2024, was $2.05 billion, up $488 million year-over-year.

• Free cash flow increased 35% to $1.4 billion year-to-date.

Outlook and guidance

• Full-year 2024 adjusted diluted EPS expected in the $6.60–$6.70 range, up 27–29% from 2023, including an $0.08 per share headwind from the surgical solutions divestiture.

• Q4 2024 adjusted diluted EPS expected between $1.75–$1.85, up 13–19% year-over-year.

• 2025 and beyond: maintain 12–15% adjusted diluted EPS growth trajectory, with a long-term goal to reach 20% operating income margin.

• One Ecolab initiative targets $175 million in restructuring costs and $50 million in special charges by 2027, with $225 million in annualized cost savings expected.